Advertisement
Home Tags Prescription Drugs

Tag: Prescription Drugs

For patients with early Parkinson disease

Levodopa + Carbidopa Does Not Modify Disease in Early Parkinson

0
Findings in patients with early Parkinson disease evaluated over the course of 80 weeks
Concurrent use of benzodiazepine receptor modulators and opioids and of nonselective and selective benzodiazepine receptor modulators increased from 1999-2000 to 2013-2014

Benzodiazepine, Opioid Co-Usage Up in the United States

0
Increases also noted in co-use of nonselective and selective benzodiazepine receptor modulators
Use of the oral hepatoselective glucokinase activator TTP399 for type 2 diabetes does not cause hypoglycemia and has no detrimental effect on plasma lipids or liver enzymes

Oral Hepatoselective Glucokinase Activator Promising in T2DM

0
Clinically significant and sustained reduction in glycated hemoglobin was observed with TTP399
A U.S. Food and Drug Administration advisory panel vote on whether to recommend approval of the first oral medication for type 1 diabetes ended in an 8-8 tie Thursday.

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

0
Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels
From 2007 to 2016

Medication Treatment for Substance Abuse Up in Facilities

0
2007 to 2016 saw increase in use of medication treatment, reaching 36.1 percent in 2016
Ertugliflozin appears safe and effective at improving long-term glycemic control among adults with type 2 diabetes mellitus inadequately controlled on metformin

Ertugliflozin Seems Safe, Effective for Type 2 Diabetes Treatment

0
Improvements seen in HbA1c, fasting glucose, body weight, blood pressure over two years
For relapsing-remitting multiple sclerosis

Risk for Conversion of MS Varies With Different Therapies

0
Lower risk for conversion for initial treatment with fingolimod, alemtuzumab, or natalizumab
The U.S. Preventive Services Task Force recommends risk-reducing medications for women at high risk for breast cancer who are at low risk for adverse events

USPSTF Recommends Risk-Reducing Meds for Breast Cancer

0
Risk-reducing medications recommended for women at high risk, not for routine use
The median overall survival from diagnosis for patients with stage IV anaplastic lymphoma kinase-positive non-small cell lung cancer is 6.8 years

Median Survival for Stage 4 ALK-Positive NSCLC Nearly 7 Years

0
Most patients in study received crizotinib; prognosis worse when more organs have tumors at diagnosis
Three classes of drugs hold potential as repurposed agents to treat patients with serious mental illness

Drug Repurposing May Provide More Psychiatric Tx Options

0
Three drug classes tied to lower rates of self-harm and psychiatric stays with serious mental illness